1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Factor VIII Deficiency: new trials by email Literature Review of Factor VIII Deficiency trials Research Report on Factor VIII Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A efanesoctocog alfa (BIVV001) - Factor VIII Deficiency | Phase 3 | Completed | Bioverativ, a Sanofi company | 159 | 2019-11-19 | 2025-09-17 |
Hemophilia A (1)
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1)
BIVV001 (1)
Bioverativ, a Sanofi company (1)
Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · South Korea (1)
PMID 36720133, PMID 39414418, PMID 39576432, PMID 39576433, PMID 39927501, PMID 40099428, PMID 41583536, PMID 41789959, PMID 42598540
2019 (1)